INNOVATIVE TECHNOLOGY FOR MONITORING & EARLY DETECTION OF CANCER
MONITORING MALIGNANCIES
THROUGH A SIMPLE BLOOD TEST
​
Non-invasive & simple liquid biopsy
​
Monitoring Multiple Malignancies
Cost effective &
Rapid
Utilizing standard lab equipment
FGL2
DISCOVER THE POWER OF FIBRINOGEN-LIKE PROTEIN (FGL2) BIOMARKER REVOLUTIONIZING CANCER MONITORING
FGL2, a serine protease, demonstrates upregulation in a multitude of malignancies including Liver, Prostate, Colon, Breast and Gastric solid tumors, yet completely absent from adjacent normal tissues surrounding malignant tumors.
​
Based upon our pioneering discovery of heightened FGL2 expression within peripheral blood cells among patients with malignancies, we developed our innovative patented non-invasive assay, designed for the detection and monitoring of malignancies.
INTRODUCING "LymFollow"
AN INNOVATIVE BLOOD TEST FOR AGGRESSIVE LYMPHOMA
Personalized
Experience
LymFollow, our remarkable diagnostic kit, introducing a simple blood test leveraging the groundbreaking Fibrinogen Like Protein 2 (FGL2).
This innovation is tailored to detect and monitor Non-Hodgkin Lymphoma (NHL) with unparalleled precision.
Unveiling a new era in diagnostics, this innovative technology enables early detection while reliably forecasting NHL progression, gauging treatment response, and anticipating relapse. Moreover, its strong correlation with PET/CT imaging further solidifies its exceptional value.
​
MULTIPLE MALIGNANCIES MONITORING
Our innovative assay has been validated across various additional malignancies including:
-
Colorectal Cancer
-
Lung Cancer
-
Mycosis Fungoides (MF)
For non-invasive differentiation of early-stage MF
from inflammatory dermatoses.
​
ADVANCED CANCER SCREENING & EARLY DETECTION
​
Our assay, designed as a comprehensive screening and early detection solution for multiple malignancies, represents a transformative paradigm shift with the capacity to revolutionize cancer care.
​
Our roadmap strategy broadens the scope of our biomarker test to encompass all critical malignancies lacking early detection biomarkers, by establishing high correlation with PET/CT and positioning our test as the benchmark screening method for malignancy detection, extending even to challenging cases such as pancreatic cancer.
OUR STORY
Following over a decade of research, Dr. Esther Rabizadeh at the helm of the Haematology Laboratory at Israel's Rabin Medical Center, assisted by Dr. Izhack Cherny, achieved a momentous breakthrough in cancer detection.
Their remarkable discovery centered around the detection of FGL2 upregulation in peripheral blood cells among patients with malignancies. This pivotal finding paved the way for the successful development of a non-invasive liquid biopsy test, enabling the monitoring of this protein's activity.
Acknowledging the groundbreaking potential, this technology secured grants from the Israel Innovation Authority and underwent thorough clinical validation for Non-Hodgkin Lymphoma.
​
Presently, the team is dedicatedly channeling their efforts into the rigorous validation of the assay across a spectrum of malignancies.
